Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome

• Published in: Rheumatology international Vol. 32; no. 1; pp. 249 - 251
• Main Authors: Shendi, Hiba M., Walsh, Deirdre, Edgar, J. David M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 2012; Springer Nature B.V
• Subjects: Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Case Report; Child; Etanercept; Female; Fever - chemically induced; Fever - physiopathology; Humans; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Interleukin 1 Receptor Antagonist Protein - adverse effects; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Medicine; Medicine & Public Health; Mevalonate Kinase Deficiency - drug therapy; Mevalonate Kinase Deficiency - physiopathology; Receptors, Tumor Necrosis Factor - therapeutic use; Rheumatology; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Treatment; Adverse effects; Etanercept; Hyper IgD and periodic fever syndrome (HIDS); Anakinra
• ISSN: 0172-8172; 1437-160X
• DOI: 10.1007/s00296-009-1322-8

Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, hereditary autoinflammatory condition, characterized by recurrent inflammatory episodes. There is no proven treatment for HIDS, but various drugs including, non-steroidal anti-inflammatory drugs, colchicine, steroids, statins and thalidomide have all been tried. Recently, some patients have demonstrated a good clinical response to either etanercept or anakinra. We report a case of a 10-year-old girl who experienced prolonged and severe inflammatory attacks, when she was treated with etanercept, and later with anakinra.